Optimapharm confirms Mirna Šenjug Novak as Group CFO
Optimapharm, a leading, mid-sized, full-service CRO (Contract Research Organization) across Europe and North America, is excited to announce the promotion of Mirna Šenjug Novak as Group Chief Financial Officer (CFO), effective February 2023
“I have proudly been a part of Optimapharm for more than 10 years and feel honored to be able to serve the company in my new position as a CFO. This team has already done amazing things and I’m excited to contribute my deep understanding of the company’s history and operations and my passion for driving growth and innovation to ensure our continued success.’’
Mirna Šenjug Novak, Chief Financial Officer
We Deliver on Your Promises
Mirna Šenjug Novak is a finance professional with over 15 years of experience in the pharmaceutical and banking industry, M&A, and integrations.
In 2012, she became a member of the Optimapharm team and proceeded to establish procedures and systems within the company’s Finance Department. She was involved in various DD processes, on the buyer side, and led several post-acquisition integrations. Several IT implementations on the customer side, such as DMS, CTMS, and accounting software were successfully delivered under Mirna’s leadership. Mirna took over the Group Chief Financial Officer (CFO) role, succeeding in her previous position as Vice President of Finance.
In her new role Mirna becomes Member of the Management Board, having demonstrated exceptional leadership and financial expertise as a key finance team member. Mirna holds an MA in Economics (major in Finance) from the University of Zagreb, Croatia, and has completed the CFA program at the CFA Institute.
